{"id":"glucagon-im","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glucagon is a peptide hormone that activates glucagon receptors (a G-protein coupled receptor) on hepatocytes, triggering intracellular signaling cascades that promote the breakdown of stored glycogen and synthesis of new glucose. This mechanism makes it effective for acute treatment of severe hypoglycemia by quickly mobilizing endogenous glucose production. The IM formulation allows for rapid absorption and onset of action in emergency settings.","oneSentence":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:06.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe hypoglycemia in patients with diabetes"}]},"trialDetails":[{"nctId":"NCT03765502","phase":"PHASE1","title":"A Study Comparing User Experience of Different Delivery Devices for Glucagon","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-19","conditions":"Healthy","enrollment":99},{"nctId":"NCT03421379","phase":"PHASE3","title":"A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-02-21","conditions":"Diabetes Mellitus","enrollment":75},{"nctId":"NCT01994746","phase":"PHASE3","title":"Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11","conditions":"Diabetes Mellitus, Type 1","enrollment":77},{"nctId":"NCT03339453","phase":"PHASE1","title":"A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-11-10","conditions":"Hypoglycemia, Diabetes Mellitus, Type 1","enrollment":70},{"nctId":"NCT01959334","phase":"PHASE3","title":"Evaluate the Immunogenicity of a Novel Glucagon Formulation","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-09","conditions":"Drug-specific Antibodies, Diabetes Mellitus","enrollment":75},{"nctId":"NCT01997411","phase":"PHASE2, PHASE3","title":"Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11","conditions":"Diabetes Mellitus, Type 1","enrollment":48},{"nctId":"NCT00745186","phase":"PHASE1","title":"Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers","status":"COMPLETED","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","startDate":"2007-08","conditions":"Hypoglycemia","enrollment":28},{"nctId":"NCT02403648","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons","status":"COMPLETED","sponsor":"Biodel","startDate":"2014-11","conditions":"Hypoglycemia","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GlucaGen® HypoKit"],"phase":"phase_3","status":"active","brandName":"Glucagon IM","genericName":"Glucagon IM","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels. Used for Severe hypoglycemia in patients with diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}